Cancer Biomarkers Market to Grow from USD 28.25 Billion in 2026 to USD 54.48 Billion by 2032, at a CAGR of 11.6% – MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2026 (GLOBE NEWSWIRE) — MarketsandMarkets™ projects the global cancer biomarkers market will grow from USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6% during the forecast period. Market growth is primarily driven by the increasing incidence of cancer, technological advancements in cancer biomarker development, growing research and development activities focused on biomarker innovation, and increasing adoption of cancer biomarkers in drug discovery and development. The growing emphasis on early cancer detection and monitoring, precision medicine, non-invasive diagnostics, and innovative genomic, proteomic, and multi-omics approaches is further supporting market expansion.
Get PDF Brochure – Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Key Market Highlights
- Market size, 2026: USD 28.25 billion
- Market forecast, 2032: USD 54.48 billion
- Growth rate: CAGR of 11.6% (2026–2032)
- Largest regional market: North America
- Fastest-growing region: Asia Pacific
- Largest profiling technology segment: Omics technologies
- Fastest-growing product segment: Consumables, at a CAGR of 12.0%
- Largest cancer type segment: Breast cancer
- Largest application segment: Diagnostics, with a 51.0% share in 2025
- Largest end-user segment: Diagnostic laboratories
- Key players: Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), and QIAGEN (Netherlands).
Why This Market Matters
The growing incidence of cancer worldwide is creating increasing demand for cancer biomarkers for early detection, monitoring, diagnosis, prognosis, and treatment selection. Cancer biomarkers are becoming an important component of precision oncology, helping healthcare professionals identify molecular characteristics of tumors and support individualized treatment decisions.
The increasing adoption of cancer biomarkers in drug discovery and development and growing investments in research and development are also contributing to market growth. The shift toward personalized medicine and targeted therapies has accelerated the use of biomarker-based diagnostics, while growing adoption of non-invasive diagnostics such as liquid biopsy is creating additional opportunities.
Market Overview
The cancer biomarkers market is witnessing rapid technological advancement across diagnostic imaging, immunoassays, omics technologies, and bioinformatics. Innovations in next-generation sequencing (NGS), PCR-based assays, and multiplex testing platforms are improving the sensitivity, specificity, and turnaround time of biomarker identification, supporting more reliable clinical decision-making.
The market is also experiencing increasing adoption of genomic and multi-omic technologies, non-invasive liquid biopsies, and AI-driven digital pathology platforms. These technologies enable more efficient detection of complex tumor mutations and support precision oncology and personalized targeted therapies. The development of pan-cancer profiling solutions and companion diagnostics is further contributing to the evolution of the market.
Analyst Perspective
The expanding role of personalized and precision medicine presents a significant opportunity for the cancer biomarkers market. Cancer biomarkers are increasingly used for diagnosis, prognosis, and selection of targeted therapies as healthcare systems move away from conventional one-size-fits-all treatment approaches. Biomarker-based diagnostics enable treatment decisions based on patients’ genetic profiles and clinical characteristics, supporting improved treatment effectiveness and clinical outcomes.
The integration of AI and multi-omics approaches is further expanding opportunities for biomarker discovery and analysis. At the same time, increasing applications of companion diagnostics in oncology and growth potential in emerging economies are creating additional opportunities for market players.
Speak to Our Analyst – Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202
Segment Analysis
By profiling technology, the cancer biomarkers market is segmented into omics technologies and imaging technologies. The omics technologies segment accounted for the largest share of the cancer biomarkers market in 2025. The increasing demand for advanced omics technologies is primarily attributed to their high-throughput capabilities.
By cancer type, the market includes breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, non-Hodgkin’s lymphoma, kidney cancer, and other cancer types. The breast cancer segment held the highest market share in 2025, supported by increasing cancer prevalence and technological advancements in cancer biomarker development.
By product, the market is segmented into consumables, instruments, and bioinformatics software. Consumables are further categorized into antibodies, kits & reagents, and probes, while instruments include imaging instruments, pathology-based instruments, and biopsy instruments. The consumables segment is expected to register the highest growth rate, with a CAGR of 12.0%, and dominated the market in 2025 owing to repeated purchases and high consumption.
By application, the market is segmented into diagnostics, research & development, prognostics, risk assessment, and other cancer applications. The diagnostics segment accounted for the largest share in 2025, with a 51.0% share, supported by the increasing prevalence of cancer, technological advancements, and the growing need for early diagnosis.
By end user, the market is segmented into diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes, and other end users. Diagnostic laboratories accounted for the largest market share in 2025, driven by the expanding number of clinical laboratories performing cancer biomarker-based diagnostic tests and the rising prevalence of malignancies.
Regional Analysis
North America led the cancer biomarkers market in 2025. The region benefits from advanced healthcare infrastructure, established diagnostic capabilities, and the presence of leading cancer biomarker companies.
Asia Pacific is expected to register the highest CAGR in the cancer biomarkers market. Growth in the region is supported by improving healthcare infrastructure, rising healthcare expenditure, a large patient population undergoing advanced diagnostic testing, and favorable healthcare policies aimed at improving cancer care. The growing number of diagnostic laboratories and biopharmaceutical companies, along with increasing awareness of early disease detection and preventive healthcare, is also expected to support regional growth.
Key Industry Trends
- Increasing incidence of cancer worldwide
- Growing emphasis on early cancer detection and monitoring
- Rising adoption of precision and personalized medicine
- Increasing use of cancer biomarkers in drug discovery and development
- Growing investments in biomarker research and development
- Rapid advancements in genomic and multi-omics technologies
- Increasing adoption of next-generation sequencing
- Growing use of non-invasive liquid biopsy
- Increasing adoption of AI-driven digital pathology
- Development of pan-cancer profiling solutions
- Increasing use of companion diagnostics in oncology
- Growing integration of AI and multi-omics approaches in biomarker discovery and analysis.
Competitive Landscape
The cancer biomarkers market includes leading global diagnostic, life sciences, and biotechnology companies. Roche, Thermo Fisher, Illumina, Agilent Technologies, and QIAGEN were identified as key star players based on their strong market presence and extensive product portfolios. These companies are pursuing strategies including product launches, expansions, strategic partnerships, acquisitions, and collaborations to strengthen their global presence and market positions.
The market also includes specialized startups and SMEs. Quest Diagnostics, Invivoscribe, Inc., and Asuragen, Inc., among others, have established strong positions in specialized niche areas of the cancer biomarkers market.
Related Reports
Biomarkers Market
Cancer Tumor Profiling Market
CONTACT: About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: https://www.marketsandmarkets.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.
